Xeris Biopharma Holdings

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company. It engages in developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first and only FDA-approved therapy for primary periodic paralysis, and Recorlev for the treatment of endogenous Cushing's syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Xeris Biopharma reports record revenue growth and outlines future plans

Xeris Biopharma's Q4 2022 performance reflects strong revenue growth and pipeline advancements, supported by a positive 2023 revenue guidance.
While facing challenges such as competitive pressures and market dynamics, the company's focus on innovation and patient-centric strategies positions them for future success.
Opportunities lie in addressing concerns around product growth, enhancing physician engagement, and pursuing new drug development for long-term growth.

Xeris Biopharma excels in Q1 with strong revenue growth and strategic partnerships

Xeris Biopharma delivered a strong Q1 performance with significant revenue growth, solid product sales, and a healthy cash position, supported by effective financial management.
While facing challenges from potential generic competition and market dynamics, the company's strategic strengths, partnerships, and innovation drive its growth trajectory.
Opportunities in expanding product lines, leveraging partnerships, and investing in R&D position Xeris for continued success and market leadership in the pharmaceutical sector.
Maintaining a balance between addressing challenges, capitalizing on opportunities, and sustaining growth momentum will be key for Xeris Biopharma's future success.

Xeris Biopharma reports record revenue, eyes growth amid challenges

Xeris Biopharma delivered robust Q2 performance, driven by strong revenue growth and key product successes.
While facing challenges like screen failures and patent appeals, the company remains focused on growth opportunities and innovation.
With a solid financial outlook, strategic partnerships, and product advancements, Xeris is poised for continued success and market expansion.

Xeris Biopharma excels in Q3, eyes growth through innovation

Xeris Biopharma delivered a strong Q3 performance with notable revenue growth and a focus on improving cash flow and operational efficiency.
The company's emphasis on innovation, market expansion through subcutaneous drug administration, and management's confidence are key strengths.
Challenges lie in a competitive market landscape and managing investor expectations without providing 2024 financial guidance.
Opportunities include acquisitions, market expansion through innovative drug administration, and attracting institutional investment through improved financial performance.

Xeris Biopharma excels in 2023, eyes sustained growth in 2024

Xeris Biopharma's strong financial performance in 2023, driven by key products and strategic initiatives, positions the company for continued growth.
While facing challenges such as generic competition and market expectations, Xeris remains focused on innovation and market expansion.
Opportunities in revenue growth, market expansion benefits, and patient base increase offer promising prospects for Xeris in 2024.
With a solid foundation of financial prudence, innovation, and growth strategies, Xeris is poised to maintain momentum and drive success in the upcoming year.

Xeris Biopharma reports robust Q1 growth and eyes healthcare partnerships

Xeris Biopharma's Q1 2024 showcased strong financial performance, with revenue growth and strategic collaborations driving optimism for the future. Despite challenges like the cybersecurity breach, the company remains focused on innovation and partnerships to address healthcare needs and reduce hospitalizations.

Xeris Biopharma achieves record revenue, eyes growth amid challenges

Xeris Biopharma's Q3 performance reflects robust revenue growth, strategic focus, and product strength, positioning the company for sustained success.
While challenges like maintaining margins and managing expenses persist, opportunities in communication, partnerships, and new product development offer avenues for future growth.
Investors can be optimistic about Xeris Biopharma's financial stability, growth prospects, and commitment to transparency, despite potential market challenges ahead.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

DURHAM, N.C., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc. (the “Company”), a leader in the field of developing inhaled therapies to treat severe respiratory and chronic diseases, today announced the appointment of Barry Deutsch as chief financial officer effective November 15, 2021.

Aerami Therapeutics Appoints Barry Deutsch as Chief Financial Officer

Matinas BioPharma Hlds

Phunware Inc

Progenity

Verb Technology Company Inc

Penny stocks to buy right now according to analysts. The post 5 Penny Stocks To Buy According To Analysts With Targets Up To 156% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Buy According To Analysts With Targets Up To 156%

Xeris Biopharma Holdings, Inc. (XERS) CEO Paul Edick on Q3 2021 Results - Earnings Call Transcript

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, and Xeris Pharmaceuticals, Inc., today announced financial results for the third quarter and first nine months ended September 30, 2021, and recent highlights, including the completion of the Strongbridge Biopharma plc acquisition on October 5, 2021. “Continued strong demand

Xeris Biopharma Reports Third Quarter 2021 Financial Results and Other Highlights

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that the Company will release its third quarter 2021 financial results before the open of the U.S. financial markets on Wednesday, November 10, 2021. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company'

Xeris Biopharma to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 10, 2021

Xeris Biopharma (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Xeris Biopharma (XERS) Report Negative Q3 Earnings? What You Should Know

The biopharma is starting to put together a string of good news advances.

Why Xeris Pharmaceuticals Is Soaring 7% Higher Today

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced a collaboration agreement with Merck , with an option to license Xeris' suspension-based formulation technology, XeriJect™, for use with undisclosed monoclonal antibodies (mAbs) for the purpose of engineering ultra-high concentration, ready-to-use formulation

Xeris Pharmaceuticals Enters Collaboration Agreement With Merck

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, will present an overview of the Company at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday, September 22, 2021, at 8:15 a.m. Eastern Time. The presentation can

Xeris Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Strongbridge Biopharma

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) (“Xeris”) today announced that its stockholders have voted to approve the previously announced proposed acquisition of Strongbridge Biopharma plc (NASDAQ: SBBP) (“Strongbridge”) by Xeris. At the special meeting of Xeris stockholders held on September 14, 2021, approximately 97% of the shares voted were cast in favor of the acquisition, representing approximately 59% of Xeris' total outstanding shares of common stock. Xeris wil

Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharma

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, will present an overview of the Company during the H.C. Wainwright 23rd Annual Global Investment Conference held virtually this year from September 13-15, 2021. The presentation

Xeris Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that the company has completed enrollment and successfully dosed all participants in a Phase 1 study of levothyroxine (XP-8121) to evaluate the pharmacokinetics, safety and tolerability, and potential for weekly dosing of the investigational, novel, su

Xeris Pharmaceuticals Completes Enrollment of Its Phase 1 Study of Levothyroxine (XP-8121)

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) today announced that a leading independent proxy advisory firm Institutional Shareholder Services (“ISS”) has recommended that Xeris stockholders vote “FOR” all proposals related to the Company's transaction with Strongbridge Biopharma plc (Nasdaq: SBBP) (“Strongbridge”). “We are pleased that ISS supports our Board's recommendation to vote “FOR” the acquisition of Strongbridge. In its report, ISS recognizes the valuation, stra

Xeris Pharmaceuticals Announces Leading Independent Proxy Advisory Firm, ISS, Recommends Xeris Stockholders Vote “FOR” the Transaction With Strongbridge Biopharma

Lipocine

Senseonics Holdings

VEON

Penny stocks with high marks from analysts right now. The post Top Penny Stocks Analysts Say To Buy, Targets Up To 200% Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks Analysts Say To Buy, Targets Up To 200% Right Now

The shares of Xeris Pharmaceuticals Inc (NASDAQ: XERS) increased 21.36% today. This is why it happened.

Xeris Pharmaceuticals Shares Increased 21.36%: Why It Happened

Xeris Pharmaceuticals Inc (NASDAQ: XERS) is trading significantly higher Monday after the company announced U.S. Food and Drug Administration approval of its New Drug Application for Gvoke for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes two years of age and older. Xeris Pharmaceuticals said it will begin manufacturing scale up immediately and it anticipates its Gvoke Kit will be available in the first quarter of 2022.

Why Xeris Pharmaceuticals Shares Traded Higher Today

The FDA has approved Xeris Pharmaceuticals Inc's (NASDAQ:XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.  Gvoke Kit is the first ready-to-use glucagon available in a single-use vial and single-use syringe kit for rescue.

Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday

CASI Pharmaceuticals

China Rapid Finance

Are these penny stocks worth the risk? The post Trending Penny Stocks To Buy For Under $3 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trending Penny Stocks To Buy For Under $3 Right Now

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that its supplemental new drug application (sNDA) of Gvoke® Kit was approved by the Food and Drug Administration (FDA) for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages 2 years and above. Gvoke Kit will be available as a

Xeris Pharmaceuticals Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke® Kit for the Treatment of Severe Hypoglycemia

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has recently been granted three new patents relating to its formulation technology platforms. The U.S. Patent and Trademark Office granted U.S. Patent Nos. 10,987,399 and 11,020,403 to Xeris, and the China Intellectual Property Office grant

Xeris Pharmaceuticals Strengthens Its Patent Estate

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced the achievement of an important milestone of payor coverage for Gvoke – a ready-to-use glucagon for the treatment of severe hypoglycemia for adults and children with diabetes ages 2 and above. Today, approximately 91% of Medicare patients, 88% of c

Xeris Pharmaceuticals Achieves Unprecedented Levels of Payor Coverage for Gvoke®

The shares of Xeris Pharmaceuticals Inc (NASDAQ: XERS) increased by over 20% pre-market. This is why it happened.

Xeris Pharmaceuticals Shares Increase Over 20% Pre-Market: Why It Happened

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the Food and Drug Administration (FDA) has allowed the Investigational New Drug Application (IND) for its XeriSol levothyroxine for hypothyroidism to proceed. The active IND enables Xeris to initiate a Phase 1 clinical study for XP-8121 using

Xeris Pharmaceuticals Announces FDA Acceptance of its IND Application for XeriSol™ Levothyroxine (XP-8121) for the Treatment of Hypothyroidism

Xeris Pharmaceuticals (XERS) delivered earnings and revenue surprises of -32.26% and -11.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Xeris Pharmaceuticals (XERS) Reports Q2 Loss, Misses Revenue Estimates

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced financial results for the second quarter and first six months ended June 30, 2021, and recent highlights. “The second quarter was extremely busy and very successful, highlighted by the proposed acquisition of Strongbridge Biopharma. We continued to see

News for Xeris Biopharma Holdings Stock (XERS)